bioRxivImmunology
Novel engineered chimeric engulfment receptors trigger T-cell effector functions against SIV infected CD4+ T cells
Abstract
Adoptive therapy with genetically engineered T cells offers potential for infectious disease treatment in immunocompromised persons. HIV/simian immunodeficiency virus (SIV) infected cells express phosphatidylserine (PS) early post-infection. We tested whether chimeric engulfment receptor (CER) T cells designed to recognize PS-expressing cells could eliminate SIV infected cells. Lentiviral CER constructs comprised of the extracellular domain of T-cell immunoglobulin and mucin domain containing 4 (TIM-4), the PS receptor, and engulfment signaling domains were transduced into primary rhesus macaque (RM) T cells. We measured PS binding and T-cell engulfment of RM CD4+ T cells infected with SIV expressing GFP. As chimeric antigen receptor (CAR) T cells induce PS and subsequent TIM-4 binding, we evaluated in vitro killing of CAR and CER T-cell combinations. We found that recombinant TIM-4 bound to SIV infected cells. In vitro, CER CD4+ T cells effectively killed SIV infected cells, which was dependent on TIM-4 binding to PS. Enhanced killing of SIV infected CD4+ T cells by CER and CAR T-cell combinations was observed. This installation of innate immune functions into T cells presents an opportunity to enhance elimination of SIV infected cells and offers potential to augment functional cure of SIV/HIV infection.
- organism: rat
- assay: proteomics
- research focus: host-pathogen & immune response
- research focus: cell type annotation
- research focus: cell signaling & trafficking
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection
M. S. Pampusch, H. M. Abdelaal, … P. J. Skinner·bioRxiv·Jul 26, 2021
- Allogeneic gene-edited HIV-specific CAR-T cells secreting PD-1 blocking scFv enhance anti-HIV activity in vitro
- Title: Combinatorial bnAb and T Cell Immunization Enhances Post-Infection Control of SHIVSF162p3 Viremia in Rhesus Macaques
Diane G Carnathan, Chiamaka A Enemuo, … George K Lewis·bioRxiv·Nov 5, 2026
- Targeting PD-1+ T-cells with Chimeric Antigen Receptors to reduce the HIV Reservoir
Laura Ermellino, Riddhima Banga, … Yannick D. Müller·Science AdvancesPeer-reviewed·Apr 24, 2026
- Broadly neutralizing antibody-secreting CAR-T cells elicit Fc-mediated effector functions in vitro and suppress HIV in humanized mice
Zoe Stylianidou, Sarah Gerlo, … Wojciech Witkowski·Frontiers in ImmunologyPeer-reviewed·May 8, 2026
- Targeted Bacteriophage T4 Nanoparticles Reverse HIV-1 Latency in CD4+ Human T Cells